TY  - JOUR
AU  - Seane, Elsie Neo
AU  - Nair, Shankari
AU  - Vandevoorde, Charlot
AU  - Joubert, Anna
TI  - Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
JO  - Pharmaceuticals
VL  - 17
IS  - 5
SN  - 1424-8247
CY  - Basel
PB  - MDPI
M1  - GSI-2024-00600
SP  - 602
PY  - 2024
N1  - This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
AB  - Histone deacetylases inhibitors (HDACis) have shown promising therapeutic outcomes in haematological malignancies such as leukaemia, multiple myeloma, and lymphoma, with disappointing results in solid tumours when used as monotherapy. As a result, combination therapies either with radiation or other deoxyribonucleic acid (DNA) damaging agents have been suggested as ideal strategy to improve their efficacy in solid tumours. Numerous in vitro and in vivo studies have demonstrated that HDACis can sensitise malignant cells to both electromagnetic and particle types of radiation by inhibiting DNA damage repair. Although the radiosensitising ability of HDACis has been reported as early as the 1990s, the mechanisms of radiosensitisation are yet to be fully understood. This review brings forth the various protocols used to sequence the administration of radiation and HDACi treatments in the different studies. The possible contribution of these various protocols to the ambiguity that surrounds the mechanisms of radiosensitisation is also highlighted.
KW  - DNA repair (Other)
KW  - double strand break (Other)
KW  - heterochromatin (Other)
KW  - histone deacetylase inhibitors (Other)
KW  - radiosensitisation (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38794172
UR  - <Go to ISI:>//WOS:001231544000001
DO  - DOI:10.3390/ph17050602
UR  - https://repository.gsi.de/record/350853
ER  -